A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 in Healthy Overweight/Obese Volunteers

NCT05900531 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: K-757
DRUG: K-757 and open-label sitagliptin
DRUG: Matching placebo to K-757
DRUG: Matching placebo to K-757 and matching placebo to K-833
DRUG: K-757 and K-833
DRUG: Matching placebo to K-757, open-label sitagliptin

Sponsor

Kallyope Inc.